 Mustang Bio Inc NASDAQ: MBIO announced interim data from the Phase 12 trial of MB-107, lentiviral gene therapy for X-linked severe combined immunodeficiency X-SCID, also known as bubble boy disease, in newly diagnosed infants under the age of two. X-SCID is characterized by the. 